Geneyork Pharmaceutical to initiate U.S. Launch of Generic Version of Deltasone® (Prednisone) Tablets

Based on latest news, privately held specialty pharmaceutical company Geneyork Pharmaceutical has announced the U.S. launch and commercial shipment of generic version of Deltasone® (Prednisone) Tablets. Sources suggest the tablets will be available in various strengths ranging from 1 mg, 2.5 mg, 5 mg, 10 mg, 20 mg, and 50 mg.

Sources suggest the company’s new venture will be in collaboration with Lannett Company, which is also reportedly Geneyork’s U.S. distribution and marketing partner.

According to experts, Prednisone, a corticosteroid, is useful in the treatment of arthritis, breathing problems, severe allergies, blood disorders, skin diseases, cancer, immune system disorders and eye problems.

Based on a report by IQVIA, the tablets held a total share of U.S. sales of $121 million for 2018.

In the wake of the new announcement, CEO of Geneyork, Isaac Liu said,  “We are proud to add Prednisone Tablets to our growing portfolio of more than 40 specialty products. The launch of Prednisone Tablets demonstrates our strong development and partnership capabilities. Geneyork continues to expand its product development portfolio and has secured nine ANDA approvals and has an additional six filed with the FDA. We have also acquired or exclusively in licensed five ANDAs. We are pleased to partner with the Lannett for this launch.”